Abstract: The conventional imaging procedure is CT in diagnosis of malignant lymphomas. However, nuclear medicine imaging has also had a prominent role. Single-photon imaging with ⁶⁷Ga-citrate(⁶⁷Ga) has been widely used for lymphomas. Positron emission tomography(PET) with, ¹⁸F-fluorodeoxyglucose(¹⁸F-FDG) has gained a role in the staging and follow-up of lymphomas, largely replacing ⁶⁷Ga as the nuclear medicine study of choice, ¹⁸F-FDG PET has proved useful in the staging, restaging, monitoring response of therapy and follow-up of Hodgkin disease and non-Hodgkin lymphoma. And the widespread use of PET-CT has also increased the sensitivity and specificity, reviewed the role of ¹⁸F-FDG PET in the management of patients with lymphoma.